Here we are, a third of the way through 2013 and already the stroke calendar is bursting with interesting meetings and exciting possible outcomes. After a very successful International Stroke Conference in Hawaii, we are now ready for another outstanding meeting at European Stroke Conference (ESC) in London where some important trial results will be released, not the least of which is INTERACT 2. International Journal of Stroke (IJS) has a strong link with this study having published the protocol, ‘The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2)’ protocol article is available at the online IJS archives, and podcasts with the principal investigator Craig Anderson are available online at iTunes. Immediately after the INTERACT 2 presentation of results, we will be doing a fast-track video interview for our YouTube channel with Craig Anderson to share the results with the readers worldwide. The use of media in this way allows rapid dissemination of this information in a way we would have never thought possible several years ago. IJS has been at the forefront of this media revolution since inception and will continue to harness new technologies as they emerge.
The synergy between cutting edge science and media technology is obvious.
In the next edition of IJS published just after ESC, we will also publish the article, ‘Statistical analysis plan for the second INTEnsive blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT2): a large-scale investigation to solve longstanding controversy over the most appropriate management of elevated blood pressure in the hyperacute phase of intracerebral hemorrhage’.
Of particular interest in this edition is the study from China concerning the use of stroke patients with oral anticoagulation, ‘Use of oral anticoagulation among stroke patients with atrial fibrillation in China’, their finding that oral anticoagulation use was only 20% overall in their cohort does suggest that the underusage of traditional vitamin K antagonists may be even more marked than in Western countries; the obvious implication is that this country of 1·3 billion people represents an enormous unmet need for the use of simpler and safer oral anticoagulants such as Factor Xa and direct thrombin inhibitors. No doubt the pharmaceutical industry appreciates this inference as well; the possibility that this may have a significant impact on the burden of stroke is compelling.
Other articles such as bed rest or mobilization after recombinant tissue-type plasminogen activator will continue to stir discussion about rehabilitation in stroke and associated controversies.
We have recently opened our blog page to Stroke Support Organizations worldwide and encourage these organizations and stroke advocates, to contact us regarding their essential activities and movements advocating for stroke education, action and change, which they do admirably all year round. Please refer to IJS guidelines for submission information or contact our Managing Editor, Carmen Lahiff-Jenkins firstname.lastname@example.org.
Looking forward to seeing what is generated.